sr141716 has been researched along with Heart Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pacher, P | 1 |
| Finn, P | 1 |
| Després, JP; McCarthy, C; Pi-Sunyer, X; Scheen, A; Van Gaal, L | 1 |
3 other study(ies) available for sr141716 and Heart Diseases
| Article | Year |
|---|---|
Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?
Topics: Animals; Atherosclerosis; Cannabinoids; Clinical Trials as Topic; Heart Diseases; Humans; Metabolic Diseases; Mice; Mice, Knockout; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, LDL; Rimonabant; Weight Gain | 2009 |
American Heart Association--scientific sessions 2005. Potential new drugs for various indications. 13-16 November 2005, Dallas, TX, USA.
Topics: American Heart Association; Animals; Cardiotonic Agents; Heart Diseases; Humans; Piperidines; Potassium Channel Blockers; PPAR delta; Pyrazoles; Rimonabant; Thiazoles | 2006 |
Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
Topics: Cannabinoid Receptor Antagonists; Cannabinoids; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diet, Reducing; Exercise; Heart Diseases; Humans; Metabolic Diseases; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Safety | 2008 |